单药曲贝替定对比医生选择化疗治疗BRCA突变和/或BRCAness表型的复发性卵巢癌患者:一项随机III期试验
MITO-23是一项前瞻性、开放标签、随机III期试验,共纳入244例BRCA1/2突变或BRCAness表型的复发性卵巢癌患者,随机接受曲贝替定1.3 mg/m2每3周一次(A组)或医生选择化疗(B组)。主要终点总生存期在两组间无显著差异,A组15.8个月对比B组17.9个月(P=0.304);曲贝替定组≥3级不良事件、严重不良事件和严重药物不良反应频率更高。
要点
- 曲贝替定组中位总生存期15.8个月对比医生选择化疗组17.9个月,无显著差异(P=0.304)。
- 曲贝替定组中位无进展生存期4.9个月对比对照组4.4个月(P=0.897)。
- 曲贝替定组≥3级不良事件、严重不良事件和严重药物不良反应频率高于对照化疗。
核心结论
- 曲贝替定对比医生选择化疗未改善中位总生存期,且安全性更差。
研究设计与样本
- 前瞻性、开放标签、随机III期MITO-23试验,纳入21个MITO中心的244例复发性卵巢癌、原发性腹膜癌或输卵管癌患者,随机分为A组122例和B组122例。
- A组接受曲贝替定1.3 mg/m2每3周一次;B组接受医生选择化疗(聚乙二醇脂质体多柔比星、拓扑替康、吉西他滨、每周一次紫杉醇或卡铂)。
- 主要终点为意向治疗人群的总生存期;入组患者中超过70%接受过≥3线既往化疗,35.7%在入组前接受过聚(ADP-核糖)聚合酶抑制剂(PARPi)。
主要发现
- 中位总生存期A组15.8个月对比B组17.9个月(P=0.304),无显著差异。
- 中位无进展生存期A组4.9个月对比B组4.4个月(P=0.897)。
- 在208例可评估疗效的患者中,客观缓解率A组17.1%对比B组21.4%,中位缓解持续时间分别为5.62个月和5.66个月。
- 按BRCA突变状态、化疗类型以及PARPi和/或铂类无治疗间期预处理进行的预设亚组分析中,曲贝替定未显示更优效果。
- 曲贝替定组≥3级不良事件、严重不良事件和严重药物不良反应的频率高于对照化疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Literature evidence suggests that trabectedin monotherapy is effective in patients with recurrent ovarian cancer (OC) presenting BRCA mutation and/or BRCAness phenotype. METHODS: A prospective, open-label, randomized phase III MITO-23 trial evaluated the activity and safety of trabectedin 1.3 mg/m2 given once every 3 weeks (arm A) in BRCA 1/2 mutation carriers or patients with BRCAness phenotype (ie, patients who responded to ≥two previous platinum-based treatments) with recurrent OC, primary peritoneal carcinoma, or fallopian tube cancer in comparison with physician's choice chemotherapy in the control arm (arm B; pegylated liposomal doxorubicin, topotecan, gemcitabine, once-weekly paclitaxel, or carboplatin). The primary end point was overall survival (OS) evaluated in the intention-to-treat population. RESULTS: Overall, 244 patients from 21 MITO centers were randomly assigned (arm A = 122/arm B = 122). More than 70% of patients received ≥three previous chemotherapy lines and 35.7% had received a poly (ADP-ribose) polymerase inhibitor (PARPi) before enrollment. Median OS was not significantly different between the arms: arm A: 15.8 versus arm B: 17.9 months (P = .304). Median progression-free survival was 4.9 months in arm A versus 4.4 months in arm B (P = .897). Among 208 patients evaluable for efficacy, the objective response rate was 17.1% in arm A and 21.4% in arm B, with comparable median duration of response (5.62 v 5.66 months, respectively). No superior effect was observed for trabectedin in the prespecified subgroup analyses according to BRCA mutational status, chemotherapy type, and pretreatment with a PARPi and/or platinum-free interval. Trabectedin showed a higher frequency of grade ≥3 adverse events (AEs), serious AEs, and serious adverse drug reactions compared with control chemotherapy. CONCLUSION: Trabectedin did not improve median OS and showed a worse safety profile in comparison with physician's choice control chemotherapy.
引用
- Lorusso D, Raspagliesi F, Ronzulli D, et al. Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial. J Clin Oncol. 2024. PMID: 38315944. doi:10.1200/JCO.23.01225
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。